Infigratinib phosphate is primarily used in the treatment of certain types of cancer, particularly those involving abnormal fibroblast growth factor receptor (FGFR) signaling. It is specifically approved for the management of cholangiocarcinoma, a rare form of bile duct cancer, in patients with FGFR2 gene fusions or rearrangements. The compound works by inhibiting FGFR activity, which helps to slow down or stop the growth and spread of cancer cells. Additionally, it is being investigated for its potential in treating other FGFR-driven cancers, such as bladder cancer and glioblastoma, offering hope for patients with limited treatment options. Its targeted approach minimizes damage to healthy cells, reducing the severity of side effects compared to traditional chemotherapy.